• Quirino Lai, Nicoletta De Matthaeis, Michele Finotti, Giovanni Galati, Giuseppe Marrone, Fabio Melandro, Filomena Morisco, Daniele Nicolini, Riccardo Pravisani, Edoardo G Giannini, and Associazione Italiana per lo Studio del Fegato (AISF) HCC Special Interest Group.
• General Surgery and Organ Transplantation Unit, AOU Policlinico Umberto I, Sapienza University of Rome, Rome, Italy.
• Eur. J. Clin. Invest. 2023 Jan 1; 53 (1): e13870e13870.

AimTo evaluate the impact of antiplatelet therapy (APT)on the incidence of hepatocellular carcinoma (HCC) and mortality following its treatment.MethodsA systematic literature search was performed using PubMed and Cochrane Central Register of Controlled Trials Databases. Two HCC clinical settings were explored: (i) incidence, and (ii) death after any HCC treatment. Odds ratios (OR) and 95% confidence intervals (95%CI) were calculated to compare the pooled data between patients who received or did not receive APT.ResultsA total of 20 studies were identified, of whom 15 focused on HCC incidence, including 2,685,009 patients, and five on post-treatment death, including 3281 patients. APT was associated with an overall reduced risk of HCC incidence (OR: 0.63; 95%CI = 0.51-0.79; p < 0.001) as well as of post-treatment mortality (OR: 0.54; 95%CI = 0.35-0.83; p = 0.006).ConclusionsCurrent data suggest that APT correlated with higher HCC incidence and poor overall survival following tumour treatment.© 2022 The Authors. European Journal of Clinical Investigation published by John Wiley & Sons Ltd on behalf of Stichting European Society for Clinical Investigation Journal Foundation.

12 keywords...

hide…